Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of biological drug products in various injectable formats. It also offers end-to-end CDMOservices across all phases of pre-clinicaland clinical development and commercialsupply of biologics[1]
Business Overview:[1]OSSPL is a subsidiary of Strides PharmaLtd. The company is a Contract Developmentand Manufacturing Organisation that catersto several biopharma and biotech companies.It covers the entire CDMO value chain, from clinical development to technology transferto commercial manufacture and regulatory assistance.
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Sun Pharma.Inds. | 1728.90 | 35.93 | 414821.02 | 0.93 | 3124.95 | 2.56 | 14478.31 | 8.93 | 20.21 | 54964.01 | 30.12 | 11543.96 | 3117.95 | 5.33 | 12.97 | 0.07 |
| 2. | Divi's Lab. | 6363.50 | 67.98 | 168930.93 | 0.47 | 689.00 | 35.10 | 2715.00 | 16.12 | 20.44 | 10029.00 | 32.37 | 2485.00 | 689.00 | 10.96 | 13.53 | 0.01 |
| 3. | Torrent Pharma. | 3869.80 | 60.45 | 130971.62 | 0.83 | 591.00 | 32.49 | 3302.00 | 14.30 | 27.05 | 12248.00 | 32.60 | 2166.53 | 600.17 | 15.50 | 13.26 | 0.33 |
| 4. | Cipla | 1519.80 | 22.56 | 122765.07 | 0.86 | 1353.37 | 3.73 | 7589.44 | 7.64 | 22.72 | 28349.57 | 25.40 | 5441.14 | 1351.17 | 3.73 | 14.72 | 0.01 |
| 5. | Dr Reddy's Labs | 1250.00 | 18.07 | 104328.80 | 0.64 | 1336.80 | 7.28 | 8828.30 | 9.83 | 22.69 | 34310.00 | 24.64 | 5772.20 | 1347.10 | 2.90 | 12.95 | 0.16 |
| 6. | Lupin | 2083.70 | 22.01 | 95183.17 | 0.58 | 1484.83 | 73.34 | 7047.51 | 24.23 | 21.30 | 24750.69 | 27.25 | 4324.63 | 1477.92 | 4.85 | 12.41 | 0.32 |
| 7. | Zydus Lifesci. | 921.95 | 18.45 | 92769.74 | 1.19 | 1238.60 | 40.92 | 6123.20 | 16.92 | 24.31 | 24493.90 | 31.10 | 5029.35 | 1283.60 | 3.67 | 14.64 | 0.38 |
| 8. | OneSource Speci. | 1796.70 | 77.89 | 20587.51 | 0.00 | 37.10 | 172.59 | 375.19 | 52.89 | 6.42 | 1510.36 | 34.29 | 264.30 | 37.10 | 3.44 | 2.93 | 0.22 |
| – | Median: 151 Co. | 410.9 | 30.9 | 1678.7 | 0.11 | 13.49 | 11.71 | 152.64 | 10.58 | 14.89 | 574.01 | 15.93 | 43.84 | 13.96 | 3.15 | 8.56 | 0.22 |
Standalone figures in ₹ crores
| Dec 2023 | Dec 2024 | Jun 2024 | Jun 2025 | Mar 2024 | Mar 2025 | Sep 2023 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|
Sales | 56 | 337 | 240 | 321 | 73 | 477 | 34 | 245 | 375 |
Expenses | 67 | 237 | 230 | 241 | 76 | 240 | 72 | 223 | 274 |
Operating Profit | -10 | 99 | 10 | 80 | -3 | 237 | -38 | 22 | 102 |
Other Income | -74 | -95 | -1 | 5 | 3 | 3 | -32 | -3 | 3 |
Profit before tax | -130 | -73 | -65 | 25 | -40 | 174 | -113 | -58 | 37 |
Tax % | 0% | 0% | -63% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Profit | -130 | -73 | -24 | 25 | -40 | 174 | -113 | -58 | 37 |
EPS in Rs | – | -6.38 | – | 2.17 | – | 15.22 | – | – | 3.24 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
Sales | 21 | 132 | 39 | 172 | 1,300 | 1,510 |
Expenses | 93 | 228 | 156 | 254 | 930 | 992 |
Operating Profit | -72 | -96 | -117 | -82 | 370 | 518 |
Other Income | 1 | 4 | -525 | -143 | -95 | -83 |
Interest | 16 | 68 | 48 | 89 | 162 | 137 |
Depreciation | 34 | 70 | 109 | 76 | 135 | 135 |
Profit before tax | -121 | -230 | -799 | -390 | -22 | 163 |
Net Profit | -121 | -230 | -799 | -390 | 19 | 163 |
EPS in Rs | – | – | – | – | 1.69 | 14.25 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | – |
Standalone figures in ₹ crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
Equity Capital | 2 | 4 | 4 | 4 | 11 | 11 |
Reserves | 777 | 1,012 | 783 | 394 | 5,909 | 5,975 |
Borrowings | 386 | 1,154 | 864 | 571 | 942 | 1,295 |
Other Liabilities | 98 | 275 | 363 | 457 | 635 | 670 |
Total Liabilities | 1,262 | 2,445 | 2,014 | 1,426 | 7,497 | 7,952 |
Fixed Assets | 633 | 1,231 | 1,361 | 863 | 3,200 | 3,353 |
Gross Block | 718 | 1,392 | 1,633 | 1,139 | 3,611 | – |
Accumulated Depreciation | 86 | 160 | 271 | 277 | 410 | – |
CWIP | 382 | 440 | 334 | 188 | 206 | 173 |
Investments | 53 | 52 | 5 | 20 | 2,848 | 2,843 |
Other Assets | 194 | 722 | 314 | 355 | 1,243 | 1,582 |
Total Assets | 1,262 | 2,445 | 2,014 | 1,426 | 7,497 | 7,952 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
Cash from Operating Activity | -115 | -420 | -165 | -109 | -47 |
Cash from Investing Activity | -210 | -685 | -66 | 506 | -300 |
Cash from Financing Activity | 381 | 1,159 | 118 | -384 | 417 |
Net Cash Flow | 56 | 55 | -112 | 13 | 70 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
Debtor Days | 38 | 101 | 35 | 118 | 124 |
Inventory Days | 87 | 1,720 | 2,354 | 665 | 233 |
Days Payable | 758 | 408 | 1,606 | 419 | 143 |
Cash Conversion Cycle | -633 | 1,414 | 784 | 363 | 214 |
Working Capital Days | -2,423 | -1,288 | -6,731 | -873 | -49 |
ROCE % | – | -10% | -12% | -12% | 6% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
Nov 2025
Sep 2025
Aug 2025
May 2025
Feb 2025
Stock Analysis
OneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited) is engaged in the research, development, manufacture, and commercialisation of biological drug products, offering end-to-end CDMO services across all phases of development and commercial supply. The company focuses on the biopharma and biotech sectors, covering the entire CDMO value chain.
Currently no data available for Order Book.
Currently no data available for Key Dates To Watch.
Corporate Announcements
